A Respiratory Syncytial Virus Replicon That Is Non-Cytotoxic and Capable of Long-Term Foreign Gene Expression

Total Page:16

File Type:pdf, Size:1020Kb

A Respiratory Syncytial Virus Replicon That Is Non-Cytotoxic and Capable of Long-Term Foreign Gene Expression A Respiratory Syncytial Virus Replicon That Is Non-Cytotoxic and Capable of Long-Term Foreign Gene Expression DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By Olga Malykhina The Integrated Biomedical Science Graduate Program The Ohio State University 2011 Dissertation Committee: Mark Peeples Douglas McCarty Michael Oglesbee Jianrong Li Copyright by Olga Malykhina 2011 Abstract Respiratory syncytial virus (RSV) infection of most cultured cell lines causes cell- cell fusion and death. Cell fusion is caused by the fusion (F) glycoprotein and is clearly cytopathic, but other aspects of RSV infection may also contribute to cytopathology. To investigate this possibility, we generated an RSV replicon that lacks all three of its glycoprotein genes and so cannot cause cell-cell fusion or virus spread. This replicon includes a green fluorescent protein gene and an antibiotic resistance gene to enable detection and selection of replicon-containing cells. Adaptive mutations in the RSV replicon were not required for replicon maintenance. Cells containing the replicon could be cloned and passaged many times in the absence of antibiotic selection, with 99% or more of the cells retaining the replicon after each cell division. Transient expression of the F and G (attachment) glycoproteins supported the production of virions that could transfer the replicon into most cell lines tested. Since the RSV replicon is not toxic to these cultured cells and does not affect their rate of cell division, none of the 8 internal viral proteins, the viral RNA transcripts, or the host response to these molecules or their activities are cytopathic. However, the level of replicon genome and gene expression is controlled in some manner, well below that of complete virus and, as such, might avoid cytotoxicity. RSV replicons could be useful for cytoplasmic gene expression in vitro and in vivo, and for screening compounds active against the viral polymerase. ii Dedication To: Elena Malykhina Serguei Malykine My Pulie iii Acknowledgments I would like to thank Mark Peeples for his guidance throughout my scientific career. Thank you everyone in Peeples’ lab for assisting me in my research through contribution of ideas and help with experiments. Specifically I would like to thank Mark Yednak for starting the replicon project, Charles Rice for the BHK-SR19-T7 cells, Russell and Joan Durbin for help with the IFN assay, Cynthia McAllister for help with flow sorting, Barb Newton and Steven Kwilas for excellent technical assistance, Beth McNally and Emilio Flano for their help with the qPCR, Rachel Fearns for the full-length RSV cDNA clone, D53/BsiWI, and Asuncion Mejias, Blerta Dimo, and Yannis Ioannidis for the help with microarrays. Additionally, I would like to thank Koi and Heather for the fun times we had in the lab together. =) This work was supported by Apath, LLC, and by grants AI047213 and HL051818 from the National Institutes of Health. PLC was supported by the NIAID, NIH Intramural Research Program. iv Vita Bachelor of Science 1998-2002 Major: Biology Minor: Chemistry North Park University Doctor of Philosophy 2004-present Integrated Biomedical Science The Ohio State University Publication Olga Malykhina, Mark A. Yednak, Peter L. Collins, Paul D. Olivo and Mark E. Peeples. 2011. A Respiratory Syncytial Virus Replicon That Is Non-Cytotoxic and Capable of Long-Term Foreign Gene Expression. J Virol, 85:4792-4801. Fields of Study Major Field: Integrated Biomedical Science Minor Field: Molecular Virology and Gene Therapy v Table of Contents Abstract…………………………………………………………………………………...ii Dedication………………………………………………………………………………..iii Acknowledgments………………………………………………………………………iv Vita………………………………………………………………………………………..v List of Illustrations……………………………………………………………………..viii Abbreviations…………………………………………………………………………....xi Chapter 1: Introduction…………………………………………………………………1 Classification…………………………………………………………………….1 The Virion………………………………………………………………………...2 The Viral Proteins……………………………………………………………….2 The F Protein…………………………………………………………….3 The G Protein……………………………………………………………5 The SH Protein…………………………………………………………..7 The M Protein……………………………………………………………8 Replication Complex Proteins………………………………………………9 The M2-1 Protein………………………………………………………11 The M2-2 Protein………………………………………………………12 The NS1 and NS2 Proteins…………………………………………..13 RNA……………………………………………………………………………..14 The RSV Life Cycle……………………………………………………………16 vi Vaccines………………………………………………………………………..20 Passive Immunization…………………………………………………24 Antiviral Agents………………………………………………………...25 Reverse Genetics……………………………………………………………...26 Infection of immortalized cells in culture.……………………………………29 Infection of experimental animals……………………………………………30 Chapter 2: The RSV Replicon………………………………………………………..32 Introduction……………………………………………………………………..32 Materials and Methods………………………………………………….…….36 Results………………………………………………………………………….44 Discussion………………………………………………………………………71 Chapter 3: Application of the RSV Replicon……………………………………..…78 Replicons that also express viral glycoprotein genes………………….…..79 Virion formation by the RSV replicon………………………………………..80 Identifying a viral mechanism(s) that controls the replication of the RSV replicon……………………………………………………………………83 Identifying a cellular mechanism(s) that controls the replication of the RSV replicon……………………………………………………………………84 Replicon-Containing Cell Line for Drug Screening……………………….105 vii List of Illustrations List of Figures Chapter 1: Figure 1.1: RSV life cycle……………………………………………………………..19 Figure 1.2: Launching recombinant green fluorescent protein expressing RSV (rgRSV) from cDNA……………………………………………………………………28 Chapter 2: Figure 2.1: Launch of the RSV Replicon from cDNA………………………………35 Figure 2.2: Derivation of the MP295 replicon cDNA……………………………….46 Figure 2.3: RT-PCR analysis of viral RNA from replicon-containing cells………48 Figure 2.4: Fluorescent photomicrograph of BHK-SR19-T7 cells containing the RSV replicon, as indicated by the expression of GFP……………………………..52 Figure 2.5: Replicon stability in cloned cells passaged with and without blastisidin……………………………………………………………………………….57 Figure 2.6: Replicon-containing cells from a clonal BHK-SR19-T7 population and clear cells that appeared in the culture during passage…………………………...60 Figure 2.7: Diagram showing the position of mutations in Rep295.2 and Rep295.5 genomes……………………………………………………………………63 Figure 2.8: Growth rate of replicon-containing cells compared to parental cells……………………………………………………………………………………...64 Figure 2.9: Level of viral genome and protein in replicon-containing cells compared to rgRSV-infected cells…………………………………………………...67 viii Chapter 3: Figure 3.1: Production of virions by replicon-containing HeLa cells……………..82 Figure 3.2: Gene Trees of expressed genes from replicon-containing A546 cells and RSV infected A549 cells at 24 hr p.i. compared to non-infected A549 control cells……………………………………………………………………………………...88 Figure 3.3: Modular Map of gene expression in replicon-containing A546 cells and RSV infected A549 cells…………………………………………………………91 Figure 3.4: Expression of pro-apoptotic genes in RSV-infected (24 h p.i.) and replicon containing A549 cells………………………………………………………..94 Figure 3.5: Expression of anti-apoptotic genes in RSV-infected (24 h p.i.) and replicon containing A549 cells………………………………………………………..94 Figure 3.6: List of genes highly overexpressed in the replicon-containing A549 cells but not RSV-infected A549 cells (24 h p.i.)…………………………………...96 Figure 3.7: List of genes highly overexpressed in RSV-infected A549 cells (24 h p.i.) but not replicon-containing A549 cells…………………………………………97 Figure 3.8: Replicon Network 1………………………………………………………99 Figure 3.9: RSV Network 19………………………………………………………...100 Figure 3.10: Side-by-side comparison of Replicon Network 1 with RSV Network 19………………………………………………………………………………………101 Figure 3.11: Replicon Network 2……………………………………………………102 Figure 3.12: RSV Network 1………………………………………………………...103 Figure 3.13: RSV Network 2………………………………………………………...104 Figure 3.14: Plasmid containing the RSV replicon cDNA with the Renilla green fluorescent protein (RrFP) gene and the humanized Renilla luciferase (hRLuc) gene……………………………………………………………………………………107 Figure 3.15: Luciferase expression driven by the ts or wt luciferase GS in RSV replicons incubated at 33°C or 38°C and shifted to 33°C………………………..110 ix List of Tables Chapter 2: Table 2.1: Interferon released by replicon-containing A549 cells, determined by bioassay………………………………………………………………………………...70 Chapter 3: Table 3.1: RSV replicon and virion cDNA constructs with a constant number of genes and with the viral glycoprotein genes in their natural positions………….80 x Abbreviations A Adenine AFP Alpha-fetal protein AU Arbitrary Units A549 Type II alveolar epithelial lung carcinoma cell line BHK Baby hamster kidney immortalized cell line BSD Blasticidin S deaminase cDNA Complementary DNA CMV Cytomegalovirus cpRSV Cold-passage RSV CsCl Cesium Chloride Cys Cysteine DAOY IFN-sensitive medulloblastoma cell line DMEM Dulbecco’s modified Eagle medium DNA Deoxyribonucleic acid DRbz Hepatitis D virus ribozyme F Fusion protein F0 Precursor form of the fusion protein F1 Larger subunit of the fusion protein formed after furin cleavage xi F2 Smaller subunit of the fusion protein formed after furin cleavage fbs Fetal bovine serum FI-RSV Formalin-inactivated RSV G Glycoprotein (attachment) G Guanine GAGs Glycosaminoglycans GAPDH Glyceraldehyde-3-phosphate dehydrogenase GE Gene end GFP Green fluorescent
Recommended publications
  • Multiple Origins of Viral Capsid Proteins from Cellular Ancestors
    Multiple origins of viral capsid proteins from PNAS PLUS cellular ancestors Mart Krupovica,1 and Eugene V. Kooninb,1 aInstitut Pasteur, Department of Microbiology, Unité Biologie Moléculaire du Gène chez les Extrêmophiles, 75015 Paris, France; and bNational Center for Biotechnology Information, National Library of Medicine, Bethesda, MD 20894 Contributed by Eugene V. Koonin, February 3, 2017 (sent for review December 21, 2016; reviewed by C. Martin Lawrence and Kenneth Stedman) Viruses are the most abundant biological entities on earth and show genome replication. Understanding the origin of any virus group is remarkable diversity of genome sequences, replication and expres- possible only if the provenances of both components are elucidated sion strategies, and virion structures. Evolutionary genomics of (11). Given that viral replication proteins often have no closely viruses revealed many unexpected connections but the general related homologs in known cellular organisms (6, 12), it has been scenario(s) for the evolution of the virosphere remains a matter of suggested that many of these proteins evolved in the precellular intense debate among proponents of the cellular regression, escaped world (4, 6) or in primordial, now extinct, cellular lineages (5, 10, genes, and primordial virus world hypotheses. A comprehensive 13). The ability to transfer the genetic information encased within sequence and structure analysis of major virion proteins indicates capsids—the protective proteinaceous shells that comprise the that they evolved on about 20 independent occasions, and in some of cores of virus particles (virions)—is unique to bona fide viruses and these cases likely ancestors are identifiable among the proteins of distinguishes them from other types of selfish genetic elements cellular organisms.
    [Show full text]
  • Mobile Genetic Elements in Streptococci
    Curr. Issues Mol. Biol. (2019) 32: 123-166. DOI: https://dx.doi.org/10.21775/cimb.032.123 Mobile Genetic Elements in Streptococci Miao Lu#, Tao Gong#, Anqi Zhang, Boyu Tang, Jiamin Chen, Zhong Zhang, Yuqing Li*, Xuedong Zhou* State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, PR China. #Miao Lu and Tao Gong contributed equally to this work. *Address correspondence to: [email protected], [email protected] Abstract Streptococci are a group of Gram-positive bacteria belonging to the family Streptococcaceae, which are responsible of multiple diseases. Some of these species can cause invasive infection that may result in life-threatening illness. Moreover, antibiotic-resistant bacteria are considerably increasing, thus imposing a global consideration. One of the main causes of this resistance is the horizontal gene transfer (HGT), associated to gene transfer agents including transposons, integrons, plasmids and bacteriophages. These agents, which are called mobile genetic elements (MGEs), encode proteins able to mediate DNA movements. This review briefly describes MGEs in streptococci, focusing on their structure and properties related to HGT and antibiotic resistance. caister.com/cimb 123 Curr. Issues Mol. Biol. (2019) Vol. 32 Mobile Genetic Elements Lu et al Introduction Streptococci are a group of Gram-positive bacteria widely distributed across human and animals. Unlike the Staphylococcus species, streptococci are catalase negative and are subclassified into the three subspecies alpha, beta and gamma according to the partial, complete or absent hemolysis induced, respectively. The beta hemolytic streptococci species are further classified by the cell wall carbohydrate composition (Lancefield, 1933) and according to human diseases in Lancefield groups A, B, C and G.
    [Show full text]
  • A Preliminary Study of Viral Metagenomics of French Bat Species in Contact with Humans: Identification of New Mammalian Viruses
    A preliminary study of viral metagenomics of French bat species in contact with humans: identification of new mammalian viruses. Laurent Dacheux, Minerva Cervantes-Gonzalez, Ghislaine Guigon, Jean-Michel Thiberge, Mathias Vandenbogaert, Corinne Maufrais, Valérie Caro, Hervé Bourhy To cite this version: Laurent Dacheux, Minerva Cervantes-Gonzalez, Ghislaine Guigon, Jean-Michel Thiberge, Mathias Vandenbogaert, et al.. A preliminary study of viral metagenomics of French bat species in contact with humans: identification of new mammalian viruses.. PLoS ONE, Public Library of Science, 2014, 9 (1), pp.e87194. 10.1371/journal.pone.0087194.s006. pasteur-01430485 HAL Id: pasteur-01430485 https://hal-pasteur.archives-ouvertes.fr/pasteur-01430485 Submitted on 9 Jan 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License A Preliminary Study of Viral Metagenomics of French Bat Species in Contact with Humans: Identification of New Mammalian Viruses Laurent Dacheux1*, Minerva Cervantes-Gonzalez1,
    [Show full text]
  • Prevention & Control of Viral Hepatitis Infection
    Prevention & Control of Viral Hepatitis Infection: A Strategy for Global Action © World Health Organization 2011. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Table of contents Disease burden 02 What is viral hepatitis? 05 Prevention & control: a tailored approach 06 Global Achievements 08 Remaining challenges 10 World Health Assembly: a mandate for comprehensive prevention & control 13 WHO goals and strategy
    [Show full text]
  • The Role of Hepatitis C Virus in Hepatocellular Carcinoma U
    Viruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinoma U. Hibner, D. Gregoire To cite this version: U. Hibner, D. Gregoire. Viruses in cancer cell plasticity: the role of hepatitis C virus in hepato- cellular carcinoma. Contemporary Oncology, Termedia Publishing House, 2015, 19 (1A), pp.A62–7. 10.5114/wo.2014.47132. hal-02187396 HAL Id: hal-02187396 https://hal.archives-ouvertes.fr/hal-02187396 Submitted on 2 Jun 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike| 4.0 International License Review Viruses are considered as causative agents of a significant proportion of human cancers. While the very Viruses in cancer cell plasticity: stringent criteria used for their clas- sification probably lead to an under- estimation, only six human viruses the role of hepatitis C virus are currently classified as oncogenic. In this review we give a brief histor- in hepatocellular carcinoma ical account of the discovery of on- cogenic viruses and then analyse the mechanisms underlying the infectious causes of cancer. We discuss viral strategies that evolved to ensure vi- Urszula Hibner1,2,3, Damien Grégoire1,2,3 rus propagation and spread can alter cellular homeostasis in a way that increases the probability of oncogen- 1Institut de Génétique Moléculaire de Montpellier, CNRS, UMR 5535, Montpellier, France ic transformation and acquisition of 2Université Montpellier 2, Montpellier, France stem cell phenotype.
    [Show full text]
  • And Giant Guitarfish (Rhynchobatus Djiddensis)
    VIRAL DISCOVERY IN BLUEGILL SUNFISH (LEPOMIS MACROCHIRUS) AND GIANT GUITARFISH (RHYNCHOBATUS DJIDDENSIS) BY HISTOPATHOLOGY EVALUATION, METAGENOMIC ANALYSIS AND NEXT GENERATION SEQUENCING by JENNIFER ANNE DILL (Under the Direction of Alvin Camus) ABSTRACT The rapid growth of aquaculture production and international trade in live fish has led to the emergence of many new diseases. The introduction of novel disease agents can result in significant economic losses, as well as threats to vulnerable wild fish populations. Losses are often exacerbated by a lack of agent identification, delay in the development of diagnostic tools and poor knowledge of host range and susceptibility. Examples in bluegill sunfish (Lepomis macrochirus) and the giant guitarfish (Rhynchobatus djiddensis) will be discussed here. Bluegill are popular freshwater game fish, native to eastern North America, living in shallow lakes, ponds, and slow moving waterways. Bluegill experiencing epizootics of proliferative lip and skin lesions, characterized by epidermal hyperplasia, papillomas, and rarely squamous cell carcinoma, were investigated in two isolated poopulations. Next generation genomic sequencing revealed partial DNA sequences of an endogenous retrovirus and the entire circular genome of a novel hepadnavirus. Giant Guitarfish, a rajiform elasmobranch listed as ‘vulnerable’ on the IUCN Red List, are found in the tropical Western Indian Ocean. Proliferative skin lesions were observed on the ventrum and caudal fin of a juvenile male quarantined at a public aquarium following international shipment. Histologically, lesions consisted of papillomatous epidermal hyperplasia with myriad large, amphophilic, intranuclear inclusions. Deep sequencing and metagenomic analysis produced the complete genomes of two novel DNA viruses, a typical polyomavirus and a second unclassified virus with a 20 kb genome tentatively named Colossomavirus.
    [Show full text]
  • Rational Engineering of HCV Vaccines for Humoral Immunity
    viruses Review To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity Felicia Schlotthauer 1,2,†, Joey McGregor 1,2,† and Heidi E Drummer 1,2,3,* 1 Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, Australia; [email protected] (F.S.); [email protected] (J.M.) 2 Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia 3 Department of Microbiology, Monash University, Clayton, VIC 3800, Australia * Correspondence: [email protected]; Tel.: +61-392-822-179 † These authors contributed equally to this work. Abstract: Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vaccines focused largely on generating T cell immunity, attention is now aimed at vaccines that gen- erate humoral immunity, either alone or in combination with T cell-based vaccines. High-resolution structures of hepatitis C viral glycoproteins and their interaction with monoclonal antibodies isolated from both cleared and chronically infected people, together with advances in vaccine technologies, provide new avenues for vaccine development. Keywords: glycoprotein E2; vaccine development; humoral immunity Citation: Schlotthauer, F.; McGregor, J.; Drummer, H.E To Include or 1. Introduction Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. The development of direct-acting antiviral agents (DAA) with their ability to cure Viruses 2021, 13, 805. https:// infection in >95% of those treated was heralded as the key to eliminating hepatitis C globally.
    [Show full text]
  • An Update on Self-Amplifying Mrna Vaccine Development
    Review An Update on Self-Amplifying mRNA Vaccine Development Anna K. Blakney 1,* , Shell Ip 2 and Andrew J. Geall 2 1 Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 1Z4, Canada 2 Precision NanoSystems Inc., Vancouver, BC V6P 6T7, Canada; [email protected] (S.I.); [email protected] (A.J.G.) * Correspondence: [email protected] Abstract: This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical and clinical data reported in the last five years and will discuss future prospects. Keywords: RNA; self-amplifying RNA; replicon; vaccine; drug delivery 1. Introduction: The Four Pillars of saRNA Vaccines In December 2019, the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus emerged, causing a respiratory illness, coronavirus disease 2019 (COVID-19), in Hubei province, China [1,2]. The virus has spread globally, with the World Health Organization (WHO) declaring it a Public Health Emergency of International concern on 30 January 2020 and a pandemic officially on 7 March 2020 [3]. There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic [4]. There has been an unprecedented research effort and global Citation: Blakney, A.K.; Ip, S.; Geall, coordination which has resulted in the rapid development of vaccine candidates and A.J. An Update on Self-Amplifying initiation of human clinical trials.
    [Show full text]
  • Hepatitis A, B, and C: Learn the Differences
    Hepatitis A, B, and C: Learn the Differences Hepatitis A Hepatitis B Hepatitis C caused by the hepatitis A virus (HAV) caused by the hepatitis B virus (HBV) caused by the hepatitis C virus (HCV) HAV is found in the feces (poop) of people with hepa- HBV is found in blood and certain body fluids. The virus is spread HCV is found in blood and certain body fluids. The titis A and is usually spread by close personal contact when blood or body fluid from an infected person enters the body virus is spread when blood or body fluid from an HCV- (including sex or living in the same household). It of a person who is not immune. HBV is spread through having infected person enters another person’s body. HCV can also be spread by eating food or drinking water unprotected sex with an infected person, sharing needles or is spread through sharing needles or “works” when contaminated with HAV. “works” when shooting drugs, exposure to needlesticks or sharps shooting drugs, through exposure to needlesticks on the job, or from an infected mother to her baby during birth. or sharps on the job, or sometimes from an infected How is it spread? Exposure to infected blood in ANY situation can be a risk for mother to her baby during birth. It is possible to trans- transmission. mit HCV during sex, but it is not common. • People who wish to be protected from HAV infection • All infants, children, and teens ages 0 through 18 years There is no vaccine to prevent HCV.
    [Show full text]
  • Multiple Replicons Constituting the Genome of Pseudomonas Cepacia 17616 HAI-PING Chengt and THOMAS G
    JOURNAL OF BACrERIOLOGY, JUlY 1994, p. 4034-4042 Vol. 176, No. 13 0021-9193/94/$04.00+0 Copyright © 1994, American Society for Microbiology Multiple Replicons Constituting the Genome of Pseudomonas cepacia 17616 HAI-PING CHENGt AND THOMAS G. LESSIE* Department ofMicrobiology, University ofMassachusetts, Amherst, Massachusetts 01002 Received 4 February 1994/Accepted 25 April 1994 Macrorestriction fragment analysis of DNA from Pseudomonas cepacia 17616, in conjunction with Southern hybridization experiments using junction fragments containing rare restriction enzyme sites as probes, indicated that this bacterium contains three large circular replicons of 3.4, 2.5, and 0.9 megabases (Mb). Inclusion of the 170-kb cryptic plasmid present in this strain gave an overall estimate of genome size of 7 Mb. Other Southern hybridization experiments indicated that the three large replicons contained rRNA genes as well as insertion sequence elements identified previously in this strain. The distribution of Swal, PacI, and Pmel sites on the three replicons was determined. A derivative of TnS-751 carrying a SwaI site was used to inactivate and map genes on the 2.5- and 3.4-Mb replicons. Mutants were isolated in which the 2.5- and 0.9-Mb replicons had been reduced in size to 1.8 and 0.65 Mb, respectively. The loss of DNA from the 2.5-Mb replicon was associated with lysine auxotrophy, P-lactamase deficiency, and failure to utilize ribitol and trehalose as carbon and energy sources. DNA fragments corresponding in size to randomly linearized forms of the different replicons were detected in unrestricted DNA by pulsed-field gel electrophoresis.
    [Show full text]
  • Single-Round Infectious Particle Production by DNA-Launched Infectious Clones of Bungowannah Pestivirus
    viruses Brief Report Single-Round Infectious Particle Production by DNA-Launched Infectious Clones of Bungowannah Pestivirus Anja Dalmann 1, Kerstin Wernike 1 , Eric J. Snijder 2 , Nadia Oreshkova 2 , Ilona Reimann 1 and Martin Beer 1,* 1 Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; anja.dalmann@fli.de (A.D.); kerstin.wernike@fli.de (K.W.) 2 Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; [email protected] (E.J.S.); [email protected] (N.O.) * Correspondence: martin.beer@fli.de Received: 15 July 2020; Accepted: 31 July 2020; Published: 4 August 2020 Abstract: Reverse genetics systems are powerful tools for functional studies of viral genes or for vaccine development. Here, we established DNA-launched reverse genetics for the pestivirus Bungowannah virus (BuPV), where cDNA flanked by a hammerhead ribozyme sequence at the 50 end and the hepatitis delta ribozyme at the 30 end was placed under the control of the CMV RNA polymerase II promoter. Infectious recombinant BuPV could be rescued from pBuPV-DNA-transfected SK-6 cells and it had very similar growth characteristics to BuPV generated by conventional RNA-based reverse genetics and wild type BuPV. Subsequently, DNA-based ERNS deleted BuPV split genomes (pBuPVDERNS/ERNS)—co-expressing the ERNS protein from a separate synthetic CAG promoter—were constructed and characterized in vitro. Overall, DNA-launched BuPV genomes enable a rapid and cost-effective generation of recombinant BuPV and virus mutants, however, the protein expression efficiency of the DNA-launched systems after transfection is very low and needs further optimization in the future to allow the use e.g., as vaccine platform.
    [Show full text]
  • Understanding Human Astrovirus from Pathogenesis to Treatment
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 6-2020 Understanding Human Astrovirus from Pathogenesis to Treatment Virginia Hargest University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Diseases Commons, Medical Sciences Commons, and the Viruses Commons Recommended Citation Hargest, Virginia (0000-0003-3883-1232), "Understanding Human Astrovirus from Pathogenesis to Treatment" (2020). Theses and Dissertations (ETD). Paper 523. http://dx.doi.org/10.21007/ etd.cghs.2020.0507. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Understanding Human Astrovirus from Pathogenesis to Treatment Abstract While human astroviruses (HAstV) were discovered nearly 45 years ago, these small positive-sense RNA viruses remain critically understudied. These studies provide fundamental new research on astrovirus pathogenesis and disruption of the gut epithelium by induction of epithelial-mesenchymal transition (EMT) following astrovirus infection. Here we characterize HAstV-induced EMT as an upregulation of SNAI1 and VIM with a down regulation of CDH1 and OCLN, loss of cell-cell junctions most notably at 18 hours post-infection (hpi), and loss of cellular polarity by 24 hpi. While active transforming growth factor- (TGF-) increases during HAstV infection, inhibition of TGF- signaling does not hinder EMT induction. However, HAstV-induced EMT does require active viral replication.
    [Show full text]